trial

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCTId NCT00709202
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 48 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2016-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-07
Primary completion
2016-05
Eligibility
ALL · 18 Years · 59 Years

Interventions & indications

Drugs
Betahistine

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Robert C Smith, M.D., Ph.DPrincipal Investigator

Sites

1 total
Orangeburg, United States

Linked catalysts

1
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Assoc — primary completion2016-05

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE2
Primary Completion Date
2016-05
Status
COMPLETED
relationships
The graph out of here
drug
Betahistine
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
Stanley Medical Research Institute
company
indication
Bipolar NOS(Not Otherwise Specified)
indication
Schizophreniform Disorder
indication
Bipolar II
indication
investigator
Robert C Smith, M.D., Ph.D
person